Efgartigimod clinical trials
Efgartigimod is named as an intervention in 12 current clinical trials in our Germany, Spain, USA, Italy, Poland, France, Belgium, UK, Israel, Austria, Netherlands, Canada, Japan, China, Czechia, Portugal, Ireland, Denmark, Norway and Switzerland registers. 8 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is argenx (9). The most-studied condition is Myasthenia Gravis.
How Efgartigimod works
All drug targets →- IgG receptor FcRn large subunit p51 antagonist AntagonistTarget: FCGRT Fc gamma receptor and transporter✓ In ChEMBL and the Guide to Pharmacology
- Generalized muscle weaknessPhase 3
- Graves diseasePhase 3
- Graves ophthalmopathyPhase 3
- Autoimmune thrombocytopenic purpuraPhase 3
- Bullous pemphigoidPhase 3
- Idiopathic inflammatory myopathyPhase 3
- Pemphigus foliaceusPhase 3
- Pemphigus vulgarisPhase 3
- Guillain-Barre syndromePhase 2/3
- DermatomyositisPhase 2/3
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4297551, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 9777, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
NICE appraisals of Efgartigimod
All NICE appraisals →NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Efgartigimod. 1 is current.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Efgartigimod for treating antibody-positive generalised myasthenia gravis NICE TA1069 | Not recommended | 4 Jun 2025 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
Patient leaflets for Efgartigimod
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Efgartigimod
12 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Efgartigimod
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Myasthenia Gravis | 6 |
| Generalized Myasthenia Gravis | 4 |
| gMG | 4 |
| Myasthenia Gravis, Generalized | 2 |
| MG | 2 |
| Primary Immune Thrombocytopenia (ITP) | 1 |
| Immune Thrombocytopenia (ITP) | 1 |
| ITP - Immune Thrombocytopenia | 1 |
| ITP | 1 |
| Immune Thrombocytopenic Purpura | 1 |
| AChR-Ab Seropositive Generalized Myasthenia Gravis | 1 |
| CIDP - Chronic Inflammatory Demyelinating Polyneuropathy | 1 |
| Myasthenia Gravis Crisis | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| argenx | 9 |
| Janssen Research & Development, LLC | 1 |
| Centre Hospitalier Universitaire de Nice | 1 |
| Rambam Health Care Campus | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Efgartigimod trials
How many clinical trials are testing Efgartigimod?
12 current trials in our Germany, Spain, USA, Italy, Poland, France, Belgium, UK, Israel, Austria, Netherlands, Canada, Japan, China, Czechia, Portugal, Ireland, Denmark, Norway and Switzerland registers name Efgartigimod as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Efgartigimod trials recruiting patients?
Yes. 8 of the 12 trials are recruiting: 7 with sites in Germany, 7 with sites in Spain, 6 with sites in USA, 6 with sites in Italy, 4 with sites in Poland, 3 with sites in France, 3 with sites in Belgium, 2 with sites in UK, 2 with sites in Israel, 2 with sites in Austria, 3 with sites in Japan, 1 with sites in China, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Ireland and 1 with sites in Switzerland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Efgartigimod clinical trials?
argenx (9), Janssen Research & Development, LLC (1), Centre Hospitalier Universitaire de Nice (1) and Rambam Health Care Campus (1). The number in brackets is how many trials each organisation leads.
Are there Efgartigimod clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Efgartigimod works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Efgartigimod works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Efgartigimod (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.